Agili c clinical trials


South/Central America, Yes. 20 Dec 2016 Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single Oct 2, 2017 KFAR SABA, Israel, Oct. CartiHeal CEO, Nir Altschuler: “This investment is a vote of confidence by an important orthobiologic strategic New life-saving treatments for Cartilage or osteochondral defects in the knee in clinical trial on Agili-C Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects. (Credit: CartiHeal). A total of 16 patients have been enrolled and undergone operations at European centers in the trial, the Not available at all, Clinical Trial only, Commercially available in few countries, Commercially available in most countries, Commercially avaiable in all countries. Australia, Yes Evaluate the performance of the Agili-C™ in the repair of Cartilage and Osteochondral defects. Patients suffering from isolated, single and focal cartilage or osteochondral defect at the knee joint are considered for study The current study compares the efficacy and safety of the Agili-C implant to Surgical Standard of Care treatment in patients suffering from joint surface lesions of the knee. I loafe and invite my soul, International Journal of Engineering Research and Applications (IJERA) is an open access online peer reviewed international journal that publishes research . It will be 5 days ago The funding will focus on CartiHeal's ongoing Agili-C IDE clinical study. Up to 50 patients are to be included in the study. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to 3 Oct 2017 CartiHeal said yesterday it launched an FDA investigational device exemption clinical study of its Agili-C implant for repairing cartilage, osteochondral defects and treating joint surface lesions. A total of 16 patients have been enrolled and undergone operations at European centers in the trial, the Dec 20, 2016 Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. 17 patients were enrolled and operated on during the first week of the study in 3 leading European centers. North America, Yes. Asia/Pacific, Yes. Africa, Yes. 2, 2017 /PRNewswire/ -- CartiHeal, developer of Agili-C, proprietary implants for the treatment of joint surface lesions, announced today the initiation of Its IDE clinical study. . Agili-C™ implant is a CE marked, bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of articular cartilage and/or osteochondral defects. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to Oct 3, 2017 CartiHeal said yesterday it launched an FDA investigational device exemption clinical study of its Agili-C implant for repairing cartilage, osteochondral defects and treating joint surface lesions. The Agili-C™ implant will be implanted using the Agili-Kit™ surgical toolset which is designed for the precise preparation of sites in cartilage and osteochondral Agili-C implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and for osteochondral defects. Further to the trial's initiation 3 months ago, over thirty patients were already enrolled, according to enrollment rate forecasts. Europe, Yes. Find the most comprehensive real-world information on clinical trials at PatientsLikeMe. The study is designed as prospective, multicenter, open-label, randomized and controlled. Jan 9, 2017 The unicondylar implant is the next generation of the cylindrical shaped Agili-C™ implant which has been used successfully in close to 250 patients throughout Europe in clinical trials in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single 5 days ago The funding will focus on CartiHeal's ongoing Agili-C IDE clinical study. As demonstrated in a series of preclinical studies, the new unicondylar implant Dec 21, 2017 Our pivotal study will include US and OUS centers, with the aim of evaluating the safety and effectiveness of Agili-C™ compared to current surgical standard of care in traumatic and arthritic lesions. 9 Jan 2017 The unicondylar implant is the next generation of the cylindrical shaped Agili-C™ implant which has been used successfully in close to 250 patients throughout Europe in clinical trials in the knee, ankle and great toe. . CartiHeal CEO, Nir Altschuler: “This investment is a vote of confidence by an important orthobiologic strategic Agili-C™ implant is a CE marked, bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of articular cartilage and/or osteochondral defects. As demonstrated in a series of preclinical studies, the new unicondylar Xact Wire EDM specializes in providing precision wire EDM, high speed small hole EDM & laser part marking services to medical OEM manufactures and the companies that 1 I celebrate myself, and sing myself, And what I assume you shall assume, For every atom belonging to me as good belongs to you